Dr Ivo Abraham Column: 1 Billion People Can Access Biosimilars; What About the Other 7 Billion?

November 30, 2022

Now that the world population has reached 8 billion, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, took a look at how high-income countries can increase accessibility to live-saving medicines to the 7 billion people who having limited access to biosimilars.

Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed

November 30, 2022

Amneal, Kashiv Launch Filgrastim Biosimilar, Releuko

November 29, 2022

Regence: Biosimilar Adoption Leads to $37 Million Reduction in Annual Spending

November 28, 2022

What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

November 27, 2022

Featured Content

Curious About the Experts' AFTER HOURS Interests?

Ha Kung Wong, JD, an advisory board member of The Center for Biosimilars®, speaks on his love of sports and his podcast Football Garbage Time that covers all the latest news in the NFL and pop culture with AJMC® Associate Editor Matthew Gavidia.

FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar

Part 8: Organon's Jim Carey Predicts Device Could Influence Which Adalimumab Biosimilars Succeed

Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains

How Biosimilars Are Making Big Pharma More Eco-Friendly

VOLTAIRE-X Findings in Patients With Chronic Plaque Psoriasis Supported Interchangeability

November 26th 2022

By Deana Ferreri, PhD

Article

The VOLTAIRE-X randomized controlled trial determined the adalimumab biosimilar BI 695501 (adalimumab-adbm, Cyltezo; Boehringer Ingelheim) met the FDA’s criteria to be designated as interchangeable with the reference product (Humira).

The Top 5 Biosimilar Articles for the Week of November 21

November 25th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of November 21, 2022.

Alvotech Snags Australian Approval for Adalimumab Biosimilar

November 24th 2022

By Skylar Jeremias

Article

Iceland-based Alvotech received regulatory approval for AVT02, its biosimilar referencing Humira (adalimumab), from the Therapeutic Goods Administration of Australia.

Rezvoglar Becomes Second Interchangeable Insulin Biosimilar

November 23rd 2022

By Skylar Jeremias

Article

The FDA has granted Eli Lilly’s long-acting insulin glargine biosimilar, Rezvoglar, an interchangeability designation, making it the second interchangeable insulin biosimilar in the United States.

Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability

November 22nd 2022

By Skylar Jeremias

Article

The Biosimilar Red Tape Elimination Act will seek to increase patient access to biosimilars by reducing switching study requirements for companies to obtain interchangeability designations.

Biocon’s Biosimilars Revenue Up 34% YoY

November 21st 2022

By Skylar Jeremias

Article

In Biocon’s second quarter of fiscal year 2023 earnings report, revenues were up 23% year over year (YoY) for the company, largely in thanks to the 34% increase in revenues for biosimilars and accounting for 42% of the total company revenue.

Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars

November 20th 2022

By Skylar Jeremias

Video

Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.

Administration for Pegfilgrastim Biosimilars Should Minimize Clinic Visits, Consider Patients’ Preferences

November 19th 2022

By Deana Ferreri, PhD

Article

A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.

The Top 5 Biosimilar Articles for the Week of November 14

November 18th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of November 14, 2022.

Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada

November 17th 2022

By Skylar Jeremias

Article

Organon Canada launches 2 biosimilars referencing Avastin (bevacizumab) and Herceptin (trastuzumab), China became the first country to approve a denosumab biosimilar, and Optum Rx, a large pharmacy benefit manager (PBM), said that it will add adalimumab biosimilars to formulary.